CA2394650A1 - Nouveaux heterocycles - Google Patents
Nouveaux heterocycles Download PDFInfo
- Publication number
- CA2394650A1 CA2394650A1 CA002394650A CA2394650A CA2394650A1 CA 2394650 A1 CA2394650 A1 CA 2394650A1 CA 002394650 A CA002394650 A CA 002394650A CA 2394650 A CA2394650 A CA 2394650A CA 2394650 A1 CA2394650 A1 CA 2394650A1
- Authority
- CA
- Canada
- Prior art keywords
- independently
- substituted
- occurrence
- absent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C07F9/4012—Esters of acyclic acids which can have further substituents on alkyl substituted by B, Si, P or a metal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Abstract
La présente invention concerne des composés de ciblage du système osseux, utilisés dans le traitement de troubles et d'états pathologiques divers, par exemble des tissus osseux.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17216199P | 1999-12-17 | 1999-12-17 | |
US17251099P | 1999-12-17 | 1999-12-17 | |
US60/172,161 | 1999-12-17 | ||
US60/172,510 | 1999-12-17 | ||
US24078800P | 2000-10-16 | 2000-10-16 | |
US60/240,788 | 2000-10-16 | ||
US09/741,619 | 2000-12-18 | ||
US09/740,653 US20020132819A1 (en) | 1999-12-17 | 2000-12-18 | Novel purinse |
US09/740,653 | 2000-12-18 | ||
US09/740,619 US6420384B2 (en) | 1999-12-17 | 2000-12-18 | Proton pump inhibitors |
PCT/US2000/034487 WO2001044258A1 (fr) | 1999-12-17 | 2000-12-18 | Nouveaux heterocycles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2394650A1 true CA2394650A1 (fr) | 2001-06-21 |
Family
ID=27538857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002394650A Abandoned CA2394650A1 (fr) | 1999-12-17 | 2000-12-18 | Nouveaux heterocycles |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1246829A1 (fr) |
JP (1) | JP2003532632A (fr) |
AU (1) | AU2439701A (fr) |
CA (1) | CA2394650A1 (fr) |
IL (1) | IL150059A0 (fr) |
WO (1) | WO2001044258A1 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1417207T3 (da) | 2000-08-04 | 2005-12-27 | Warner Lambert Co | Fremgangsmåde til fremstilling af 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-oner |
AU2002315389A1 (en) * | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
WO2003000011A2 (fr) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Nouvelles pyridopyrimidines et leur utilisation |
EP1408985A4 (fr) * | 2001-06-21 | 2006-03-22 | Ariad Pharma Inc | Nouveaux pyridopyrimidones et leurs utilisations |
TW200413381A (en) | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
US7384937B2 (en) | 2002-11-06 | 2008-06-10 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
WO2004063195A1 (fr) * | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Inhibiteurs de kinases a base de pyridopyrimidine |
CA2564994A1 (fr) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Composes de morpholine substitues permettant de traiter des troubles du systeme nerveux central |
BRPI0613146B8 (pt) * | 2005-06-17 | 2021-05-25 | Univ Texas | uso terapêutico de inibidores de src quinase |
CN101421269A (zh) | 2006-01-13 | 2009-04-29 | 环状药物公司 | 酪氨酸激酶抑制剂及其用途 |
SI2526934T1 (sl) | 2006-09-22 | 2016-04-29 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
WO2008054827A2 (fr) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation |
US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
WO2010019511A2 (fr) | 2008-08-13 | 2010-02-18 | Targanta Therapeutics Corp. | Rifamycines phosphonées et leurs utilisations pour la prévention et le traitement d'infections des os et des articulations |
JP5590040B2 (ja) | 2008-11-12 | 2014-09-17 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのピラジノピラジンおよび誘導体 |
US8674095B2 (en) | 2008-12-19 | 2014-03-18 | Afraxis Holdings, Inc. | Compounds for treating neuropsychiatric conditions |
WO2011044535A2 (fr) | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles de snc |
MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
WO2011156646A2 (fr) * | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 8-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc |
WO2012031228A2 (fr) | 2010-09-02 | 2012-03-08 | The Regents Of The University Of California | Conjugués llp2a-biphosphonate pour traitement de l'ostéoporose |
WO2013032527A1 (fr) | 2011-09-02 | 2013-03-07 | The Regents Of The University Of California | Conjugués llp2a-bisphosphonate pour le traitement de l'ostéoporose |
BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
JP6113185B2 (ja) | 2011-12-22 | 2017-04-12 | ジェロン・コーポレーションGeron Corporation | テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
KR20150015021A (ko) | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
PE20151495A1 (es) | 2012-11-15 | 2015-10-23 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas |
EP3027192A4 (fr) | 2013-08-02 | 2017-03-22 | Pharmacyclics, LLC | Méthodes permettant de traiter des tumeurs solides |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
EP4115886A1 (fr) | 2013-10-25 | 2023-01-11 | Pharmacyclics LLC | Procédés de traitement et de prévention de la maladie du greffon contre l'hôte |
WO2015143400A1 (fr) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Mutations de phospholipase c gamma 2 et associées aux résistances |
CA2959602A1 (fr) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
WO2016022942A1 (fr) | 2014-08-07 | 2016-02-11 | Pharmacyclics Llc | Nouvelles formulations d'un inhibiteur de la tyrosine kinase de bruton |
RU2017133990A (ru) | 2015-03-03 | 2019-04-05 | Фармасайкликс Элэлси | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона |
CN104829620A (zh) * | 2015-04-08 | 2015-08-12 | 重庆华邦胜凯制药有限公司 | 一种制备氨基吡咯[2,3-d]嘧啶衍生物的方法 |
US10899884B2 (en) | 2018-11-29 | 2021-01-26 | International Business Machines Corporation | Flame-retardant polyetheretherketone-based compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0085321B1 (fr) * | 1982-01-27 | 1986-08-27 | Schering Aktiengesellschaft | Dérivés d'acides diphosphoniques et préparations pharmaceutiques les contenant |
EP0084822B1 (fr) * | 1982-01-27 | 1986-01-08 | Schering Aktiengesellschaft | Dérivés d'acides diphosphoniques et préparations pharmaceutiques les contenant |
DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4687768A (en) * | 1984-12-21 | 1987-08-18 | The Procter & Gamble Company | Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism |
IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
AU4859493A (en) * | 1992-10-09 | 1994-05-09 | Upjohn Company, The | Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories |
SE9402001D0 (sv) * | 1994-06-09 | 1994-06-09 | Leiras Oy | Pyridylbisphosphonates for use as a therapeutical agent |
-
2000
- 2000-12-18 CA CA002394650A patent/CA2394650A1/fr not_active Abandoned
- 2000-12-18 JP JP2001544748A patent/JP2003532632A/ja not_active Withdrawn
- 2000-12-18 IL IL15005900A patent/IL150059A0/xx unknown
- 2000-12-18 EP EP00988160A patent/EP1246829A1/fr not_active Withdrawn
- 2000-12-18 AU AU24397/01A patent/AU2439701A/en not_active Abandoned
- 2000-12-18 WO PCT/US2000/034487 patent/WO2001044258A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2439701A (en) | 2001-06-25 |
WO2001044258A1 (fr) | 2001-06-21 |
IL150059A0 (en) | 2002-12-01 |
JP2003532632A (ja) | 2003-11-05 |
EP1246829A1 (fr) | 2002-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2394650A1 (fr) | Nouveaux heterocycles | |
US20020103161A1 (en) | Novel heterocycles | |
US7645747B2 (en) | Therapeutic phosphonate compounds | |
US6214812B1 (en) | Bisphosphonate conjugates and methods of making and using the same | |
EP1778249B1 (fr) | Prodrogues phosphonate d'un analogue de la 2'-fluoro-2',3'-didéhydro-2',3'-didésoxyadénosine comme agents anti-vih | |
KR100358327B1 (ko) | 포스포네이트뉴클레오티드에스테르유도체 | |
TWI389908B (zh) | 抗病毒化合物類 | |
EA011399B1 (ru) | Трициклические соединения - ингибиторы интегразы вич, способ их получения (варианты), фармацевтическая композиция на их основе, способ ее получения и способы их использования в лечении болезней | |
KR20020093824A (ko) | 포스포네이트 뉴클레오티드 화합물 | |
EP1259520B1 (fr) | Nouvelles purines | |
TW200408645A (en) | Non nucleoside reverse transcriptase inhibitors | |
CA2394654A1 (fr) | Inhibiteurs de la pompe a protons | |
EP1244679B1 (fr) | Derives de la purine | |
KR20000029705A (ko) | 뉴클레오타이드동족체 | |
US7598246B2 (en) | Bisphosphonate conjugates and methods of making and using the same | |
US6197775B1 (en) | Phosphonate nucleotide derivatives | |
US20020142994A1 (en) | Bisphosphonate conjugates and methods of making and using the same | |
CN114516789B (zh) | 环丙烯酮类小分子化合物及其合成方法和应用 | |
CA3003741A1 (fr) | Conjugues de bortezomib et leurs methodes d'utilisation | |
US10660884B2 (en) | Phosphonate-chloroquine conjugates and methods using same | |
WO2003077928A1 (fr) | Analogues de peptides et utilisations | |
JP3148139B2 (ja) | ホスホナートヌクレオチド化合物 | |
Ndubaku et al. | Orally Bioavailable Small Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression Through Blockade of Adenosine Production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |